Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants. This is the title of Richard van Breemen's and partners new lab study which takes a look at cannabinoids as therapeutic agents complimentary to the vaccines.
The study showed the compounds CBGa & CBDa blocking the SAR-CoV-2 spike protein from entering the human epithelial cells. These epithelial cells make up the tissue found in our digestive tracts, lungs, and airway. It also showed the same results for the alpha and beta variants of the SARS virus.
It is great to see the continued therapeutics effects of cannabinoids being studied and then those studies later fueling future clinical trials. Our goal at GRAMS is to simply learn with you, while offering innovative and bioavailable delivery methods for these amazing compounds.
Back to News from Grams Inc